Aligos Therapeutics’ (ALGS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research note released on Wednesday morning,Benzinga reports. They currently have a $50.00 price objective on the stock.

Other analysts have also issued reports about the company. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Finally, UBS Group started coverage on Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aligos Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $35.00.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $7.57 on Wednesday. The company has a market capitalization of $46.86 million, a price-to-earnings ratio of -0.88 and a beta of 2.67. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $13.69. The company’s fifty day moving average price is $7.68 and its two-hundred day moving average price is $8.99.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, topping the consensus estimate of ($2.09) by $0.18. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. As a group, analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in Aligos Therapeutics in the fourth quarter valued at approximately $215,000. SummitTX Capital L.P. bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at approximately $1,299,000. Verition Fund Management LLC bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at approximately $664,000. Marshall Wace LLP acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $2,504,000. Finally, Jane Street Group LLC acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $226,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.